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METHODS OF MANUFACTURING 
BIOACTIVE GELS FROM EXTRACELLULAR 
MATRIX MATERIAL 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation application of a co-pend-
ing U.S. application Ser. No. 14/332,465, filed Jul. 16, 2014, 
which is a continuation application of U.S. application Ser. 
No. 14/174,980, filed Feb. 7, 2014, now granted U.S. Pat. No. 
8,802,436, issued on Aug. 12, 2014, which claims priority to 
and benefit of U.S. Provisional Application No. 61/762,437, 
filed Feb. 8, 2013, the entire content of each of which is 
incorporated by reference herein for all purposes. 
GOVERNMENT SUPPORT 
This invention was supported by grant no. NCC 9-58 from 
the National Space Biomedical Research Institute through 
NASA. The Government has certain rights in the invention. 
TECHNICAL FIELD OF THE INVENTION 
The present invention is related to methods of manufactur-
ing bioactive gels from extracellular matrix material and their 
uses for restoration of tissues in a patient. 
BACKGROUND 
Biologic scaffolds composed of extracellular matrix mate-
rial (ECM) have been used for the repair of variety of tissues 
including the lower urinary tract, esophagus, myocardium 
and musculotendinous tissues, often leading to tissue-specific 
constructive remodeling with minimal or no scar tissue for-
mation. 
Although uses of ECM as scaffolds for preclinical and 
clinical tissue engineering and regenerative medicine 
approaches to tissue reconstruction are very promising, chal-
lenges remain in the process to manufacture bioactive gels 
from ECM, which retain their bioactivity. 
The methods of manufacturing bioactive gels from ECM 
described in the prior art require the use of enzymes and are 
time consuming because they require aggressive purification 
steps, which may lead to depletion in the bioactivity of the 
gels and may present additional regulatory barriers to mar-
keting. 
Thus, a need exists to manufacture bioactive gels from 
ECM which avoids cumbersome preparation and purification 
steps yet result in gels that retain the bioactivity of the original 
material. 
SUMMARY OF THE INVENTION 
The present invention generally pertains to improved 
methods of manufacturing bioactive gels from ECM which 
retain sufficient bioactivity to positively assist intissue repair. 
The present invention utilizes reagents that do not introduce 
additional regulatory burdens for market approval or clear-
ance of the gel invention. Thus, the invention describes meth-
ods of manufacturing bioactive gels from an ECM compris-
ing (a) providing the ECM from one or more of the group 
consisting of but not limited to small intestine submucosa 
(SIS), urinary bladder submucosa (UBS), urinary bladder 
matrix (UBM) (includes epithelial basement membrane), 
porcine dermis (PD), and liver basement membrane (LBM), 
(b) particularizing the ECM to a particle size in the range of 
2 
about 1 µm to about 1000 µm, (c) solubilizing concentrations 
in the range of about 0.5 to 11% weight/volume (w/v) of 
particularized powder in sodium hydroxide (NaOH) in the 
range of 0.1 to 1.0 M for periods of time ranging from about 
5 1 hour to about 48 hours at 4° C., (d) neutralizing the solubi-
lized ECM prepared in step (c) with hydrochloric acid (HCl), 
optionally equimolar relative to NaOH, ranging from 0.1 to 
1M to form the gel, and (e) optionally, freezing the neutral-
ized solubilized ECM prepared in step (d), optionally (f) 
10 lyophilizing the frozen ECM prepared in step (e), and option-
ally (f) reconstituting the lyophilized gel in water or saline. 
The advantages provided by the methods of manufacturing 
bioactive gels in the above manner are that aggressive purifi-
cation steps, which are deleterious to bioactivity, tedious to 
15 perform or are time consuming, and which increase the regu-
latory burden (e.g. FDA approval), are avoided. 
BRIEF DESCRIPTION OF THE DRAWINGS 
20 	 FIG.1 shows the FGF-2 content (pg/mg) of gels following 
various solubilization conditions in NaOH according to 
embodiments of the invention. All gels not marked with a % 
w/v were done at 7.0% w/v UBM to NaOH. All gels in FIG. 
1 were done at 7.0% w/v UBM to NaOH. 
25 FIG. 2 shows the VEGF content (pg/mg) of gels following 
various solubilization conditions in NaOH according to 
embodiments of the invention. All gels not marked with a % 
w/v were done at 7.0% w/v UBM to NaOH. All gels in FIG. 
1 were done at 7.0% w/v UBM to NaOH. 
30 
DETAIL DESCRIPTION 
The present invention is directed to methods of manufac-
turing bioactive gels from ECM, i.e., gels which retain suffi- 
35 cient bioactivity to positively assist tissue repair by decreas-
ing the time needed for repair, decreasing scar tissue 
formation, and improving restoration of the injured tissue to 
its pre-damaged native structure and function as compared to 
injured tissues not treated with the bioactive gel according to 
40 the invention. The gel invention and methods of making 
described herein serves as scaffolds for preclinical and clini-
cal tissue engineering and regenerative medicine approaches 
to tissue reconstruction. Bioactivity in the ECM gel according 
to the invention is in the range of about 0 to 100%, 25-75%, 
45 10-25%, less than 10%, less than 5% or less than 1% of the 
bioactivity of one or more bioactive molecules in the native 
ECM from which the gel was derived. As will be described in 
detail below, these manufacturing methods take advantage of 
a new recognition that bioactive gels from ECM can be cre- 
5o ated by solubilizing a particularized ECM in a basic (greater 
than pH 7) environment, which when neutralized with acid 
provides bioactive gels. 
In accordance withthe inventive methods, the ECM may be 
derived from layers of native mammalian tissues including 
55 but not limited to submucosa, dennis, epithelial basement 
membrane, or from tissues such as aponeurosis, fascia, ten- 
don, ligament, smooth and skeletal muscle and treatment 
site-specific ECM. The native mammalian tissue source may 
be porcine, bovine, ovine, allogenic, or autogenic, for 
60 example. For example, the ECM may be SIS (small intestinal 
submucosa), UBS (urinary bladder submucosa) or UBM (uri- 
nary bladder matrix) or liver basement membrane (LBM) 
described in U.S. Pat. No. 6,576,265, U.S. Pat. No. 6,579,538, 
U.S. Pat. No. 5,573,784, U.S. Pat. No. 5,554,389, U.S. Pat. 
65 No. 4,956,178, and U.S. Pat. No. 4,902,508, each of which 
are incorporated by reference herein. In one embodiment of 
the invention, the ECM is derived from a mammalian tissue 
US 9,238,091 B2 
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and comprises bioactive components of the extracellular 
matrix material that are arranged and in quantities similar to 
those in the tissue in its native form. 
In accordance with the inventive method, the ECM derived 
from any one of the above sources is particularized, i.e., the 
size of the ECM particles are in a range of about 1 µm to about 
1000 µm. In one embodiment, particularization of the ECM 
prior to subjecting the ECM to a basic environment provides 
homogeneity to the ECM, i.e., provides a more uniform com-
position in comparison to ECM from individual animals, 
decreasing the impact of inter-donor variability. In another 
embodiment, the particularization of the ECM facilitates in 
solubilizing the matrix in a basic environment by increasing 
surface area to volume ratio. 
The particulate ECM product, e.g., particularized ECM, is 
manufactured by grinding/milling or otherwise performing a 
size reduction process to ECM typically but not exclusively 
originally provided in sheet form. The resulting particulate 
can be any desired range of density for example in the range 
of about 0.1 g/cm3 -10 g/cm3 , about 0.10.1 g/cm 3 -1 g/cm3 or 
about 1 g/cm 3, and particle size for example in the range of 
about 1 micron-1000 microns, about 200-700 microns, about 
300-600 microns, or about 400 microns. 
A basic environment is provided by solutions of alkaline 
compounds. Alkaline compounds which could be used in 
accordance with the invention are metal hydroxides which 
include, but are not limited to, LiOH, NaOH, KOH, RbOH, 
and CsOH. Alkaline compounds which could be used in 
accordance with the invention also include weak bases, such 
as but not limited to, ammonia (NH 3), pyridine (Cs HsN), 
hydroxylamine (HzNOH), methylamine (NH 2CH3) and the 
like. Alkaline compounds are generally used at a concentra-
tion ranging from 0.1 Molar to 1.0 Molar, although concen-
trations lower that 0.1 Molar or higher than 1.0 Molar are also 
contemplated in an embodiment of the invention. 
Concentrations of particularized ECM to NaOH (w/v) are 
in the range of 0.1 % to about 20%, in particular 0.5% to 11 %, 
and more particular, 7%. 
The solubilization step at 4° C. (i.e., digestion) of the 
particularized ECM can extend over a period of time ranging 
from a few minutes to several hours (e.g., 30 minutes to 48 
hours) or days (e.g., 3-7 days), 30 minutes to 12 hours, 12-24 
hours, 24 to 36 hours, 36 to 48 hours, or two to seven days. In 
an embodiment of the invention, it is contemplated that the 
time period required for the digestion step is determined by 
the size of the particularized extracellular matrix material 
and/or the concentration of the metal hydroxide used for 
solubilization. For example, if the concentration of an alka-
line compound, such as NaOH, is low, longer incubation, i.e., 
longer time period for solubilization may be required. After 
the solubilization step in a basic solution, the solubilized 
ECM (i.e., the gel form) is neutralized to a neutral pH using 
molar concentrations, e.g., equimolar concentrations of an 
acid in a volume sufficient for the solubilized ECM to reach 
pH 6.8 to 7.4. Acids, which aid in neutralization of the ECM 
gel, can be selected from weak or strong acids. Selectivity of 
acids forthe neutralization step depends onthe salts which are 
produced when an acids reacts with the basic environment 
during neutralization. The resulting salt should be biocom-
patible. For example, in an embodiment of the invention, 
hydrochloric acid (HCl) is used to neutralize the basic envi-
ronment created by the base NaOH because the resulting salt 
(i.e., NaCI) is clinically acceptable. 
Following neutralization, optionally, gels can be subjected 
to various dwell periods, 1-48 hours, 12-36 hours, or 36 to 48 
hours to promote refolding of denatured bioactive compo-
nents. Dwell periods are generally performed with or without 
shaking or stirring the gel in a cold room (i.e., at temperature 
of about 4° C.), alternatively at room temperature. Dwell 
periods could extend beyond 48 hours to a few days, for 
example, 3-7 days to promote restructuring of the gel. 
5 According to the method of the invention, once the gel is 
neutralized it may optionally be subjected to one or more 
steps of freeze drying cycles to facilitate the conversion of the 
neutralized gel to a powder (having a neutral pH). The powder 
can be reconstituted into a gel without altering its bioactivity 
10 by mixing the powder with a liquid, such as water, or a buffer 
solution which maintains the neutral pH of the gel. In addi-
tion, preservation of bioactivity of ECMs may be achieved 
through lyophilization. 
In one embodiment according to the invention, the freeze 
15 dried, solubilized ECM is reconstituted using water and two 
3 mL syringes. One syringe contains the lyophilized gel, the 
other water, and they are mixed together via a connecter 
between the two syringes. The mixture is injected back and 
forth several times to achieve mixing. Various concentrations 
20 of ECM in NaOH can be tested for handling properties (i.e. 
injectability, tackiness, viscosity) to determine their ability to 
be applied using the two syringe system. The final consis-
tency of all gels is foam-like, and each one adheres to the 
surface to which it is applied while also maintaining consis- 
25 tency, which may be desirable in zero gravity conditions, for 
example, in space. Accordingly, the gel invention may be 
used for tissue repair during space exploration. 
In one embodiment, to the solubilized and neutralized 
ECM gel, particularized ECM is added to increase the vis- 
30 cosity orthe bioactivity of the gel. For example, UBM powder 
in the size range of about 1 micron-1000 microns, about 
200-700 microns, about 300-600 microns, about 100 to 400 
microns, about 200 microns or about 400 microns is added to 
a UBM gel prepared by the above methods to enhance the 
35 viscosity or the bioactivity of the gel, that is, the gel has better 
handling or the gel is made capable of producing a higher 
concentration of bioactive molecules, for example, growth 
factors, such as FGF, e.g., FGF-2, CTGF, or VEGF. ECM 
powder can be added, prior to, during, or after the gels are 
40 neutralized. 
In a particular embodiment, 7.0% UBM to 100 mM NaOH 
solubilized at 4° C. is used to manufacture the bioactive gel. 
A dwell period may or may not be used. UBM powder may be 
added to the gel to increase viscosity and/or bioactivity. 
45 
EXEMPLIFICATIONS 
For the following exemplifications, any number of ECM 
products such as but not limited to one or more of isolated 
50 urinary bladder submucosa, small intestinal submucosa, der-
mis, for example, could be used. In the following exemplifi-
cations, UBM, an ECM isolated from the urinary bladder and 
having epithelial basement membrane is used as an exem-
plary ECM. However the invention disclosed herein is not 
55 limited to UBM and is applicable to any isolated ECM. 
In an exemplification, gels were created using various con-
centrations of particularized UBM (0.5-11%w/v) solubilized 
in various concentrations of NaOH (0.1-1.OM). UBM was 
solubilized for various time periods (1-48 hours) in its respec- 
60 tive concentration of UBM and NaOH at 4° C. In order to test 
whether the UBM could restructure after solubilization, gels 
were also made using various dwell periods (1-48 hours) 
following neutralization. 
UBM gels created in the above manner were tested in vitro 
65 for bioactive molecular content. In this study, growth factor 
(e.g., FGF-2, CTGF, VEGF) content was analyzed. Data for 
FGF-2 and VEGF content following solubilization for each 
US 9,238,091 B2 
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gel structure is shown in FIGS.1 and 2. Lower concentration 
gels (1-6%) are not shown but produced similar results. As 
shown in FIGS.1 and 2, FGF-2 and VEGF, particularly VEGF 
levels increased in these studies. 
In one study it was found that using 7.0% w/v UBM to 
various range of NaOH with 24 hours of solubilizing at 4° C. 
and no dwell period had significantly influenced the FGF-2 
and VEGF contents in the gel. FGF-2 and VEGF contents 
were measure by standard ELISA procedures. 
What is claimed is: 
1. A method for assisting tissue repair in a patient, com-
prising: 
providing a bioactive wound healing material comprising a 
gelled extracellular matrix material in a basic solution 
wherein the extracellular matrix material is derived from 
the extracellular matrix of a mammal and comprises a 
concentration of ECM to a base (w/v) in the range of 
0.1 % to about 20%, wherein said wound healing mate-
rial is gelled at room temperature; and 
applying an effective amount of said bioactive wound heal-
ing material to injured tissue to improve restoration of 
said injured tissue to pre-injured native tissue structure 
and function. 
2. The method of claim 1 wherein bioactivity of said bio-
active wound healing material is in the range of about 
0-100%, 25-75%, or 10-25% of the bioactivity of one or more 
bioactive molecules of the native ECM from which the mate-
rial was derived. 
3. The method of claim 1 wherein said ECM is small 
intestine submucosa (SIS). 
4. The method of claim 1 wherein said bioactive wound 
healing material has a pH 6.8 to 7.4. 
5. The method of claim 1 wherein said bioactive wound 
healing material comprises FGF. 
6. The method of claim 1 wherein said assisted tissue repair 
comprises decreasing time needed for repair or decreasing 
scar tissue formation. 
6 
7. The method of claim 1 wherein the gelled bioactive 
wound healing material further comprises particularized 
ECM. 
8. The method of claim 7 wherein the particularized ECM 
5 is in size range of about 1 micron-1000 microns. 
9. The method of claim 1 wherein said bioactive wound 
healing material is lyophilized. 
10. The method of claim 1 wherein the solution comprises 
water. io 
11. The method of claim 1 wherein the solution comprises 
a buffer. 
12. The method of claim 1 wherein said ECM is urinary 
bladder submucosa (UBS). 
15 13. The method of claim 1 wherein said ECM is liver 
basement membrane (LBM). 
14. The method of claim 1 wherein said ECM is porcine 
dermis (PD). 
15. The method of claim 1 wherein said ECM is urinary 
20 bladder matrix (UBM). 
16. The method of claim 1 wherein said bioactive wound 
healing material comprises FGF-2. 
17. The method of claim 1 wherein said bioactive wound 
25 healing material comprises CTGF. 
18. The method of claim 1 wherein said bioactive wound 
healing material comprises VEGF. 
19. The method of claim 7 wherein the particularized ECM 
is in size range of about 200-700 microns. 
30 20. The method of claim 7 wherein the particularized ECM 
is in size range of about 300-600 microns. 
21. The method of claim 7 wherein the particularized ECM 
is in size range of about 100-400 microns. 
35 . 22. The method of claim 7 wherein the particularized ECM 
is in size range of about 200-400 microns. 
